Portico Transcatheter Aortic Valve Implantation System

FDA premarket approval P190023 · Aortic valve, prosthesis, percutaneously delivered

PMA numberP190023

Approval

Applicant
Abbott Medical
Received
September 9, 2019
Decision date
September 17, 2021 (APPR)
Supplements
32, latest July 9, 2026
Product code
NPT – Aortic Valve, Prosthesis, Percutaneously Delivered

Official FDA PMA record

Approval order statement

Approval for the Portico Transcatheter Aortic Valve Implantation System. The device is indicated for relief of aortic stenosis in patients with symptomatic heart disease due to severe native calcific aortic stenosis who are judged by a heart team, including a cardiac surgeon, to be at high or greater risk for open surgical therapy (i.e., predicted risk of surgical mortality >= 8% at 30 days, based on the Society of Thoracic Surgeons (STS) risk score and other clinical comorbidities unmeasured by the STS risk calculator).